SARS CoV 2 News and Research

RSS

Researchers develop synthetic defective SARS-CoV-2 genome that inhibits viral replication

A shorter genome comprising only a part of the SARS-CoV-2's RNA genome competes with the normal virus for growth and can potentially prevent viral replication.

26 Nov 2020

Antihypertensive drugs may reduce COVID-19 mortality in at-risk patients

A new multicenter study that recently appeared on the medRxiv* preprint server in November 2020 has found a lower or equal risk of fatal COVID-19 in hypertensive patients, depending on the type of medication they are on.

26 Nov 2020

Phycobilins found to inhibit SARS-CoV-2 enzymes in vitro

Researchers have released an interesting new study that describes the broad-spectrum of antiviral activity that phycobilins can have. Phycobilins, which are bioactive plant compounds, were found to inhibit two coronavirus enzymes.

26 Nov 2020

Study shows lower light pollution during COVID-19 lockdown in Granada

A novel study reports a favorable change in light pollution during the lockdown in Granada, Spain, from March to May 2020, and has traced it back to several different causes related to COVID-19 lockdown measures.

26 Nov 2020

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

Specific SARS-CoV-2 genomic variations are associated with higher COVID-19 deaths

A team of scientists from South Korea and the United States has conducted an interesting study to investigate whether mutations in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect the severity of coronavirus disease 2019 (COVID-19). The study findings reveal that mutations in the viral spike protein and RNA polymerase complex can increase the risk of COVID-19 mortality.

25 Nov 2020

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer is poised for clinical testing to begin in December.

25 Nov 2020

Study sheds new light on genetic risk factors that make individuals susceptible to severe COVID-19

Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill.

25 Nov 2020

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

In a recent cutting-edge study, US researchers unveiled an anti-staphylococcal enterotoxin B monoclonal antibody that can be repurposed to target the cleavage site of the SARS-CoV-2 spike glycoprotein and, in turn, inhibit viral infection. Their findings are currently available on bioRxiv preprint server.

25 Nov 2020

SARS-CoV-2 likely circulating in China as early as mid-October 2019

Researchers in the United States have conducted a modeling study suggesting that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – could have been circulating in the Chinese province of Hubei as early as mid-October 2019.

25 Nov 2020

Genomic analysis provides clues about SARS-CoV-2 ancestry and transmission

Researchers in the UK conducting a genomic analysis of severe acute respiratory virus syndrome coronavirus 2 (SARS-CoV-2) and SARS-like coronaviruses in the bat and pangolin have identified strong host-associated divergences that could provide clues about the ancestry and interspecies transmission of SARS-CoV-2.

25 Nov 2020

Researchers discover close SARS-CoV-2-relative in animal hosts outside China

In a major new discovery that might deepen our understanding of SARS-CoV-2’s animal origins and its genetic evolution, coronaviruses very closely related to SARS-CoV-2 have been discovered in two horseshoe bats outside of China.

25 Nov 2020

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

A recent study based at a hospital in Buenos Aires, Argentina, found that convalescent plasma therapy for patients with severe COVID-19, and COVID-19-related pneumonia, was largely ineffective.

25 Nov 2020

Computational model can help predict cellular drug targets against COVID-19

A computational model of a human lung cell has been used to understand how SARS-CoV-2 draws on human host cell metabolism to reproduce by researchers at the University of Warwick.

25 Nov 2020

Researchers explore prevention measures for SARS-CoV-2 transmission during international travel

Researchers from the Centres for Disease Prevention and Control (CDC) have released findings of their study on the transmission of SARS-CoV-2 via international travel.

25 Nov 2020

Study: None of the SARS-CoV-2 mutations appear to increase transmissibility in humans

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers.

25 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Is COVID-19 severity mediated by higher antibody response?

A new study indicates that patients with more severe COVID-19 have a stronger antibody response.

25 Nov 2020

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

A study conducted by researchers based in Italy suggests that SARS-CoV-2 induces durable and strong immunity in patients who had moderate to severe COVID-19.

25 Nov 2020

Researchers review key elements of crisis decision making during public health emergencies

In mid-March, public health officials across the San Francisco area issued the first U.S. regional shelter-in-place order in response to the emerging COVID-19 pandemic.

25 Nov 2020

SARS CoV 2 News and Research

Researchers develop synthetic defective SARS-CoV-2 genome that inhibits viral replication

Antihypertensive drugs may reduce COVID-19 mortality in at-risk patients

Phycobilins found to inhibit SARS-CoV-2 enzymes in vitro

Study shows lower light pollution during COVID-19 lockdown in Granada

Early interferon therapy may mitigate COVID-19 severity

Specific SARS-CoV-2 genomic variations are associated with higher COVID-19 deaths

COVID-19 vaccine candidate tested preclinically at UAB poised for Phase 1 clinical study

Study sheds new light on genetic risk factors that make individuals susceptible to severe COVID-19

Inhibiting SARS-CoV-2 cell entry with monoclonal antibodies against staphylococcal enterotoxin B superantigen

SARS-CoV-2 likely circulating in China as early as mid-October 2019

Genomic analysis provides clues about SARS-CoV-2 ancestry and transmission

Researchers discover close SARS-CoV-2-relative in animal hosts outside China

Convalescent plasma therapy ineffective in treating severe COVID-19, study finds

Computational model can help predict cellular drug targets against COVID-19

Researchers explore prevention measures for SARS-CoV-2 transmission during international travel

Study: None of the SARS-CoV-2 mutations appear to increase transmissibility in humans

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Is COVID-19 severity mediated by higher antibody response?

Robust antibody response to SARS-CoV-2 can persist for eight months, study finds

Researchers review key elements of crisis decision making during public health emergencies

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News